Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
By T. Mok, Yi-Long Wu, S. Thongprasert, Chih-Hsin Yang, Da-Tong Chu, N. Saijo, P. Sunpaweravong, Baohui Han, B. Margono, Y. Ichinose and 9 more. New England Journal of Medicine, 2009
1,152 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/2849a9b94003627559484a5969d7f8feb3c065d1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Advances in understanding cancer genomes through second-generation sequencing (2010, background): “For example, treatment with the inhibitors of the epidermal growth factor receptor kinase (EGFR), gefitinib and erlotinib, leads to a significant survival benefit in patients with lung cancer whose tumours carry EGFR mutations, but no benefit in patients whose tumours carry wild-type EGFR”
- Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, methodology): “A statistically significant PFS was found for all patients in the trial treated with gefitinib, including those whose tumors were EGFR mutation positive.(61) The updated systematic review included final OS results, which were not statistically significantly different (overall: 18.”
- Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation (2010, neutral): “Copyright © 2010 American Association for Cancer Research mutant lung cancers, the reported prevalence of “de novo” T790M has varied widely (1% to 38%)(3, 17, 18, 40, 41), with the upper end of this range possibly reflecting false positive results with some T790M assays.”